Mr. Antoine Pau serves as a Partner at Truffle Capital. He served as a Finance Director, Director of Life Sciences Investment, Investment Manager of Life Sciences and Head of Life Sciences Investment at the firm. Mr. Pau joined Truffle Capital in 2008 as Director of Life Sciences Investment and focused on life sciences. He is a Chemist and also an Adjunct Lecturer at Science Po Paris and Pierre and Marie Curie University (Sorbonne). He spent the last three years at Mazars, where he audited pharmaceutical and biotechnology companies and investment funds. He joined Mazars as Financial Auditor where he worked for three years managing the legal audits and statutory auditing of pharmaceutical and biotech companies as well as investment funds and also participated in the financial due diligence process for tech companies in the Transaction Services department. He started his career with Novartis Pharma (Novartis AG) in the Business Planning and Analysis team (Oncology Business Unit). He serves as an Independent Director of Vexim SA. Mr. Pau served as a Director of Vexim SA from March 19, 2012 to May 16, 2015. He served as a Director TheraDiag SA until April 27, 2017. He serves as a Director at Biokinesis, Vexim, Deinobiotics, Diaccurate, ABIVAX S.A. and BMD. Mr. Pau holds an M.B.A. and Msc in Management from the ESSEC Business School and a Pharmacy degree.

Deinobiotics, Biokinesis